Market Closed -
Other stock markets
|
|
Pre-market 09:13:37 am | ||
49.88 USD | -0.70% | 50.46 | +1.16% |
02:29pm | Bristol-Myers Squibb Adds $3 Billion to Buyback Program | MT |
02:16pm | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo and Yervoy Achieved Primary Endpoint | MT |
ETFs positioned on Bristol-Myers Squibb Company
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.97% | 323 M€ | -7.50% | - | |
6.42% | 18 M€ | -7.82% | - | |
6.03% | 16 M€ | 0.00% | - | |
5.00% | 820 M€ | -4.99% | - | |
5.00% | 11 M€ | 0.00% | - | |
5.00% | 68 M€ | 0.00% | - | |
4.99% | 2 M€ | 0.00% | ||
4.89% | 27 M€ | -5.68% | - | |
4.89% | 132 M€ | -7.45% | - | |
4.89% | 16 M€ | 0.00% | - | |
4.80% | 7 M€ | +4.74% | - | |
4.68% | 1 M€ | -.--% | - | |
4.68% | 12 M€ | -6.24% | - | |
4.68% | 50 M€ | -6.77% | - | |
4.54% | 5 M€ | 0.00% | ||
4.54% | 1 M€ | -.--% | ||
4.47% | 362 M€ | +0.75% | ||
4.45% | 33 M€ | -3.33% | ||
4.36% | 3 M€ | -14.16% | ||
4.21% | 10 M€ | -.--% | ||
4.03% | 169 M€ | +4.87% | - | |
4.01% | 26 M€ | +9.53% | - | |
3.99% | 161 M€ | -6.89% | ||
3.92% | 475 M€ | -4.32% | - | |
3.91% | 8 M€ | 0.00% | - | |
3.88% | 331 M€ | +1.83% | - | |
3.31% | 79 M€ | 0.00% | ||
3.18% | 76 M€ | -5.74% | ||
3.16% | 44 M€ | 0.00% | - | |
3.06% | 27 M€ | -14.47% | - | |
3.04% | 4 M€ | 0.00% | - | |
3.01% | 12 M€ | -.--% | ||
2.96% | 13 M€ | -1.47% | - | |
2.96% | 89 M€ | -2.84% | - | |
2.85% | 10 M€ | +10.40% | - | |
2.73% | 47 M€ | +2.70% | ||
2.72% | 109 M€ | +8.50% | ||
2.66% | 3 M€ | -9.57% | ||
2.63% | 2 M€ | -3.09% | - | |
2.63% | 14 M€ | +12.19% | - | |
2.61% | 309 M€ | -1.43% |
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
49.88USD
Average target price
64.13USD
Spread / Average Target
+28.58%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.67% | 101 B $ | |
+61.07% | 530 B $ | |
+43.20% | 438 B $ | |
-11.34% | 377 B $ | |
-4.79% | 268 B $ | |
-9.42% | 258 B $ | |
-13.34% | 230 B $ | |
+0.55% | 200 B $ | |
-9.61% | 198 B $ | |
-43.81% | 163 B $ |
- Stock
- Equities
- Stock Bristol-Myers Squibb Company - Nyse
- Funds and ETFs Bristol-Myers Squibb Company